3 New Strong Buy Ratings from Top-Rated Analysts: 02/19/2026

All of these stocks have excellent Zen Ratings — and the backing of Wall Street’s brightest and best. 

• Viatris (VTRS) — Buybacks and debt cuts fueling an undervalued comeback
• Tenet Healthcare (THC) — Record hospital demand is sending this stock to multi-year highs
• Hasbro (HAS) — Blockbuster licensing deals spark a 6-year stock high

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

1. Tenet Healthcare Corp (NYSE: THC)

Recent quarterly earnings surged for this diversified general hospital operator as hospital and surgery demand continues to grow, with the stock hitting multi-year highs following strong Q4 2025 results.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $231.10 — get current quote

Max 1-year forecast: $288.00

Why we're watching:

• Analyst support: Impressive coverage from 15 analysts with 13 Strong Buy and 2 Buy ratings reflects overwhelming bullish sentiment on the healthcare provider's trajectory. See the ratings
• Truist Securities' David S Macdonald (a top 9% rated analyst) recently maintained a Strong Buy rating with a $270.00 price target, recognizing the company's strong operational momentum.
• UBS researcher A.J. Rice (top 10%) maintains a Strong Buy with the highest price target of $288.00, representing +22.95% upside potential from current levels.
• Industry ranking context: THC is currently the 9th highest-rated stock in the Medical Care Facility industry, which has an Industry Rating of A, placing it among elite healthcare operators.
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — THC's positioning in this category reflects strong fundamental and momentum characteristics.
• Component Grades: The stock demonstrates balanced strength with B grades in Value and Financials, supported by solid profitability metrics including a 6.5% profit margin and strong operating cash flow generation. See all 7 Zen Component Grades here

2. Hasbro Inc (NASDAQ: HAS)

The famed toy company's digital pivot is delivering results, with recent announcements of major licensing deals including Harry Potter, K-pop Demon Hunters, and Voltron toys driving the stock to a 6-year high.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $102.45 — get current quote

Max 1-year forecast: $118.00

Why we're watching:

• Analyst support: Strong backing from 9 analysts with 7 Strong Buy and 1 Buy rating demonstrates confidence in the company's transformation strategy. See the ratings
• Citigroup researcher James Hardiman (a top 8% rated analyst) recently maintained a Strong Buy rating with a $118.00 price target following the company's Q4 2025 earnings beat and strong fiscal 2026 guidance.
• Industry ranking context: HAS is currently the 2nd highest-rated stock in the Leisure industry, demonstrating its leadership position within the consumer discretionary toy sector.
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — Hasbro's inclusion reflects its exceptional Growth grade of A and Financials grade of A, with a robust 16.8% profit margin.
• Component Grades: The stock stands out with an A grade in both Growth and Financials, indicating strong earnings momentum and solid balance sheet management despite elevated debt-to-equity ratios typical for consumer brands. See all 7 Zen Component Grades here

3. Viatris (NASDAQ: VTRS)

This global healthcare company is gaining momentum following strategic initiatives focused on buybacks and debt reduction, with analysts highlighting the stock's attractive valuation at current multiples.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $15.70 — get current quote

Why we're watching:

• Analyst support: Coverage from 3 analysts with 2 Strong Buy ratings and 1 Hold rating shows emerging positive sentiment. See the ratings
• Argus Research recently upgraded the stock to Strong Buy with a $15.00 price target, expressing confidence that "buybacks and debt reduction should ramp the bottom line" while noting the stock trades at an attractive low multiple. 
• Interestingly, the stock has already soared through this projection. This is part of why it was just selected as our Stock of the Week — in his recent commentary, our Zen Investor Editor-in-Chief, Steve Reitmeister, weighed in on several reasons why the stock could continue to outperform.
• Industry ranking context: VTRS is currently the 10th highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of B.
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — VTRS is among the highest-potential tickers we track in our 4600+ stock database.
• Component Grades: The stock shows balanced strength with B grades in Growth, Momentum, Sentiment, and Safety, indicating solid fundamentals across multiple dimensions. See all 7 Zen Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.